Department of Dermatology, School of Medicine, University of New Mexico, Albuquerque, New Mexico, USA.
Dermatol Online J. 2022 Jan 15;28(1). doi: 10.5070/D328157059.
Merkel cell carcinoma (MCC) is a rare neuroendocrine neoplasm, warranting surgical excision with sentinel lymph node biopsy. In later stages, adjuvant chemotherapy and radiation are required owing to its aggressive malignant behavior. We describe a 62-year-old woman who presented with multifocal recurrence of MCC and was not a candidate for immunotherapy or surgery. The patient underwent four treatments of intratumoral talimogene laherparepvec (TVEC) and demonstrated a complete response with no histologic evidence of remaining MCC on four scouting biopsies. Although TVEC therapy is currently approved for the treatment of advanced stage melanoma, it is still being investigated in MCC. This case supports the use of TVEC as monotherapy in select patients with locally advanced MCC who are not candidates for surgery or systemic immunotherapy.
默克尔细胞癌（Merkel cell carcinoma，MCC）是一种罕见的神经内分泌肿瘤，需要手术切除并进行前哨淋巴结活检。由于其侵袭性恶性行为，在晚期还需要辅助化疗和放疗。我们描述了一位 62 岁女性，她患有 MCC 多处复发性疾病，不适合免疫治疗或手术。该患者接受了 4 次肿瘤内注射替莫唑胺拉帕替拉（talimogene laherparepvec，TVEC）治疗，4 次探查性活检均未见 MCC 组织学证据，显示完全缓解。虽然 TVEC 疗法目前已被批准用于治疗晚期黑色素瘤，但仍在 MCC 中进行研究。本病例支持在不能进行手术或全身免疫治疗的局部晚期 MCC 患者中，将 TVEC 作为单一疗法使用。
